Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 4/2010

01-04-2010 | Thoracic Oncology

Pathologic Response after Neoadjuvant Therapy is the Major Determinant of Survival in Patients with Esophageal Cancer

Authors: Kenneth L. Meredith, Jill M. Weber, Kiran K. Turaga, Erin M. Siegel, Jim McLoughlin, Sarah Hoffe, Melis Marcovalerio, Nilay Shah, Scott Kelley, Richard Karl

Published in: Annals of Surgical Oncology | Issue 4/2010

Login to get access

Abstract

Background

Esophageal cancer remains a malignancy with high morbidity and mortality despite improvements to diagnosis, staging, chemotherapy, radiation, and surgery. Neoadjuvant therapy (NT) may improve oncologic outcome in many patients, however the degree to which patients benefit remains unclear. We examined the relationship between pathologic response to NT and magnitude of benefit in patients with esophageal cancer.

Methods

Using a comprehensive esophageal cancer database, we identified patients who underwent esophagectomy between 1994 and 2008. Pathologic response was denoted as complete (pCR), partial (pPR), and nonresponse (NR). Clinical and pathologic data were compared using Fisher’s exact and chi-square when appropriate, while Kaplan–Meier estimates were used for survival analysis.

Results

We identified 347 patients who underwent esophagectomy, and 262 (75.5%) were treated with NT. The median age was 66 years (28–86 years) with median follow-up of 20 months (1–177 months). There were 106 (40.5%) patients exhibiting pCR, 95 (36.3%) with pPR, and 61 (23.3%) with NR. The rate of R0 resections was higher amongst pCR (100%) compared with 94.7% in pPR (P = 0.02) and 87.5% in NR (P = 0.0007). There were 15 (14.2%) recurrences in pCR, 22 (23.7%) in pPR, and 17 (28.8%) in NR (P = 0.04). Patients achieving pCR had 5-year disease-free survival (DFS) and overall survival (OS) of 52% and 52%, respectively, compared with 36% and 38% in pPR and 22% and 19% in NR (P < 0.0001, P < 0.0001).

Conclusions

Esophageal cancer patients frequently succumb to their disease. However, patients treated with neoadjuvant therapy who achieve pCR have a higher rate of R0 resections, fewer recurrences, and improved 5-year OS and DFS.
Literature
1.
Reynolds JV, Muldoon C, Hollywood D, et al. Long-term outcomes following neoadjuvant chemoradiotherapy for esophageal cancer. Ann Surg. 2007;245(5):707–16.CrossRefPubMed
2.
Lagergren J. Adenocarcinoma of oesophagus: what exactly is the size of the problem and who is at risk? Gut . 2005;54(Suppl 1):i1–5.CrossRefPubMed
3.
Law S, Wong J. What is appropriate treatment for carcinoma of the thoracic esophagus? World J Surg 2001;25(2):189–95.CrossRefPubMed
4.
Pera M, Manterola C, Vidal O, Grande L. Epidemiology of esophageal adenocarcinoma. J Surg Oncol. 2005;92(3):151–9.CrossRefPubMed
5.
6.
Earlam R, Cunha-Melo JR. Oesophageal squamous cell carcinoma: I. A critical review of surgery. Br J Surg. 1980;67(6):381–90.CrossRefPubMed
7.
Muller JM, Erasmi H, Stelzner M, et al. Surgical therapy of oesophageal carcinoma. Br J Surg. 1990;77(8):845–57.CrossRefPubMed
8.
Wu PC, Posner MC, Wu PC, Posner MC. The role of surgery in the management of oesophageal cancer. Lancet Oncol. 2003;4(8):481–8.CrossRefPubMed
9.
Hulscher JB, van Sandick JW, de Boer AG, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus [see comment]. New Engl J Med. 2002;347(21):1662–9.CrossRefPubMed
10.
Chu KM, Law SY, Fok M, Wong J. A prospective randomized comparison of transhiatal and transthoracic resection for lower-third esophageal carcinoma. Am J Surg. 1997;174(3):320–4.CrossRefPubMed
11.
Rizzetto C, DeMeester SR, Hagen JA, et al. En bloc esophagectomy reduces local recurrence and improves survival compared with transhiatal resection after neoadjuvant therapy for esophageal adenocarcinoma. J Thorac Cardiovasc Surg. 2008;135(6):1228–36.CrossRefPubMed
12.
Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer [see comment]. New Engl J Med. 2006;355(1):11–20.CrossRefPubMed
13.
Bosset JF, Gignoux M, Triboulet JP, et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. New Engl J Med. 1997;337(3):161–7.CrossRefPubMed
14.
Burmeister BH, Smithers BM, Gebski V, et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial [see comment]. Lancet Oncol. 2005;6(9):659–68.CrossRefPubMed
15.
Gebski V, Burmeister B, Smithers BM, et al. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis [see comment]. Lancet Oncol. 2007;8(3):226–34.CrossRefPubMed
16.
Jin J, Liao Z, Zhang Z, et al. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery. Int J Radiat Oncol Biol Phys. 2004;60(2):427–36.PubMed
17.
Kelsen DP, Ginsberg R, Pajak TF, et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer [see comment]. New Engl J Med. 1998;339(27):1979–84.CrossRefPubMed
18.
Naughton P, Walsh TN, Naughton P, Walsh TN. Pre-operative chemo-radiotherapy improves 3-year survival in people with resectable oesophageal cancer. Cancer Treat Rev. 2004;30(1):141–4.CrossRefPubMed
19.
Pennathur A, Luketich JD, Landreneau RJ, et al. Long-term results of a phase II trial of neoadjuvant chemotherapy followed by esophagectomy for locally advanced esophageal neoplasm. Ann Thorac Surg. 2008;85(6):1930–6; discussion 1936–7.CrossRefPubMed
20.
Walsh TN, Grennell M, Mansoor S, et al. Neoadjuvant treatment of advanced stage esophageal adenocarcinoma increases survival. Dis Esoph. 2002;15(2):121–4.CrossRef
21.
Kelsen DP, Winter KA, Gunderson LL, et al. Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer [see comment]. J Clin Oncol. 2007;25(24):3719–25.CrossRefPubMed
22.
Meluch AA, Greco FA, Gray JR, et al. Preoperative therapy with concurrent paclitaxel/carboplatin/infusional 5-FU and radiation therapy in locoregional esophageal cancer: final results of a Minnie Pearl Cancer Research Network phase II trial [see comment]. Cancer J. 2003;9(4):251–60.CrossRefPubMed
23.
Rohatgi P, Swisher SG, Correa AM, et al. Characterization of pathologic complete response after preoperative chemoradiotherapy in carcinoma of the esophagus and outcome after pathologic complete response. Cancer. 2005;104(11):2365–72.CrossRefPubMed
24.
Walsh TN, Noonan N, Hollywood D, et al. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma [see comment] [erratum appears in N Engl J Med 1999 Jul 29;341(5):384]. New Engl J Med. 1996;335(7):462–7.
25.
Urba SG, Orringer MB, Turrisi A, et al. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma [see comment]. J Clin Oncol. 2001;19(2):305–13.PubMed
26.
Tepper J, Krasna M, Niedzwiecki D, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: (CALGB 9781). J Clin Oncol. 2008;26(7):1086–92.CrossRefPubMed
27.
Chirieac LR, Swisher SG, Ajani JA, et al. Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer. 2005;103(7):1347–55.CrossRefPubMed
28.
Mandard AM, Dalibard F, Mandard JC, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer. 1994;73(11):2680–6.CrossRefPubMed
29.
Darnton SJ, Archer VR, Stocken DD, et al. Preoperative mitomycin, ifosfamide, and cisplatin followed by esophagectomy in squamous cell carcinoma of the esophagus: pathologic complete response induced by chemotherapy leads to long-term survival [see comment]. J Clin Oncol. 2003;21(21):4009–15.CrossRefPubMed
30.
Green FL, Page DL, Fleming ID, et al. AJCC cancer staging manual, 6th ed. New York, NY: Springer-Verlag; 2002. pp. 111–9.
31.
MRC. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet. 2002;359:1727–33.
32.
Luketich JD, Schauer PR, Meltzer CC, et al. Role of positron emission tomography in staging esophageal cancer. Ann Thorac Surg. 1997;64(3):765–9.CrossRefPubMed
33.
Weber WA, Ott K, Becker K, et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol. 2001;19(12):3058–65.PubMed
34.
McLoughlin JM, Melis M, Siegel EM, et al. Are patients with esophageal cancer who become PET negative after neoadjuvant chemoradiation free of cancer? J Am Coll Surg. 2008;206(5):879–86; discussion 886–7.CrossRefPubMed
35.
Bedenne L, Michel P, Bouche O, et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102 [see comment]. J Clin Oncol. 2007;25(10):1160–8.CrossRefPubMed
36.
Ajani JA, Winter K, Komaki R, et al. Phase II randomized trial of two nonoperative regimens of induction chemotherapy followed by chemoradiation in patients with localized carcinoma of the esophagus: RTOG 0113. J Clin Oncol. 2008;26(28):4551–6.CrossRefPubMed
Metadata
Title
Pathologic Response after Neoadjuvant Therapy is the Major Determinant of Survival in Patients with Esophageal Cancer
Authors
Kenneth L. Meredith
Jill M. Weber
Kiran K. Turaga
Erin M. Siegel
Jim McLoughlin
Sarah Hoffe
Melis Marcovalerio
Nilay Shah
Scott Kelley
Richard Karl
Publication date
01-04-2010
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 4/2010
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-009-0862-1

Other articles of this Issue 4/2010

Annals of Surgical Oncology 4/2010 Go to the issue

Gastrointestinal Oncology

Neoadjuvant Docetaxel, Capecitabine and Cisplatin (DXP) in Patients with Unresectable Locally Advanced or Metastatic Gastric Cancer

Head and Neck Oncology

Long-Term Single-Center Results of Management of Ethmoid Adenocarcinoma: 95 Patients over 28 Years

Healthcare Policy and Outcomes

Cost Modeling of Preoperative Axillary Ultrasound and Fine-Needle Aspiration to Guide Surgery for Invasive Breast Cancer

Head and Neck Oncology

Outcome Analysis of Patients with pN2 Oral Cavity Cancer

Hepatobiliary Tumors

Tumor Marker Evolution: Comparison with Imaging for Assessment of Response to Chemotherapy in Patients with Colorectal Liver Metastases

Translational Research and Biomarkers

KRAS Mutation in Colon Cancer: A Marker of Resistance to EGFR-I Therapy